ESG

A new star-studded series celebrates Shenzhen's rise. Beyond the screen, it reveals a carefully crafted blueprint for national branding and economic ambition.

Maker's Mark's new partnership with the player-owned Unrivaled league is more than a sponsorship; it's a strategic bet on the future of sports.

A new $500M USACE contract shows how Tetra Tech is turning advanced AI and data analytics into profitable solutions for America's toxic waste problems.

Facing federal overhaul and public outcry, top organizations pledge reform. Can innovation and transparency fix a broken system and save thousands of lives?

Domestic manufacturing, massive power demands from AI and EVs, and a skilled labor shortage are converging to define a pivotal year for American industry.

A former oil driller pivots to advanced recycling, but can its plastics-to-fuel plant navigate financial risks and environmental scrutiny in Texas?

Marriott's latest survey and massive points giveaway reveal a strategic pivot to capture a historic shift in consumer spending from goods to travel.

An Austin firm’s massive growth to $30B AUM reveals a key trend: specialized asset managers are becoming the new architects of our connected future.

LRN appoints Bob Lemmond as CEO, a strategic move signaling a deeper push into data-driven ethics amid rising AI regulations and market complexity.

A Texas vehicle maker is deploying its Bitcoin into regulated DeFi. Is this a risky gamble or the new blueprint for corporate finance innovation?

New data reveals a massive, quiet market for spiritual wellness among younger generations. Investors are taking note of platforms monetizing this trend.

A new narcolepsy drug could finally offer patients what they've been missing: a single nightly dose with low sodium, transforming lives and the market.

A new patent for reactivated carbon technology offers a circular solution to destroy "forever chemicals," promising a reliable path for U.S. water safety.

A.D.A.M. Innovations just launched ALUNAÉ, the world's first AI genomic-based skincare. Is this the future of beauty or a step too far?

The waterpark giant is investing millions to trade slides for serenity. We analyze Kalahari's strategic leap into the booming luxury experience market.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

A deep-tech firm is harvesting metal from the ocean. Discover how this innovation could redefine sustainable luxury construction and create new market hotspots.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.